Hoth Therapeutics

Hoth Therapeutics P/B

The P/B (Price-to-Book Ratio) of Hoth Therapeutics (HOTH) as of Nov 4, 2026 is 2.33. In the previous year, P/B (Price-to-Book Ratio) was 2.08 — a change of 11.84% (higher).

P/B

2.33

YoY

11.84%

Last updated:

P/B (Price-to-Book Ratio) of Hoth Therapeutics is 2025 2.33 . P/B (Price-to-Book Ratio) of Hoth Therapeutics was 2024 2.08 . It decreases by 11.84% higher compared to the previous year.

The Hoth Therapeutics P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
92.45 USD
Jan 1, 2019
5.98 USD
Jan 1, 2020
3.08 USD
Jan 1, 2021
1.45 USD
Jan 1, 2022
2.80 USD
Jan 1, 2023
1.50 USD
Jan 1, 2024
2.08 USD
Jan 1, 2025
2.33 USD
The Hoth Therapeutics P/B history
YEARP/BYoY
2.33+11.84%
2.08+38.66%
1.50-46.30%
2.80+92.95%
1.45-52.99%
3.08-48.42%
5.98-93.53%
92.45+664.34%
12.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Hoth Therapeutics Stock analysis

What does Hoth Therapeutics do? Hoth Therapeutics, Inc. develops new generation therapies for dermatological disorders and related conditions. The company focuses on products like HT-001 for atopic dermatitis, HT-KIT for mast-cell derived cancers, HT-TBI for traumatic brain injury, and HT-ALZ for neuroinflammatory diseases including Alzheimer’s. It also develops HT-003, HT-004, and HT-002 in preclinical stages, alongside a diagnostic device using mobile technology. The firm targets medical professionals and patients seeking advanced treatments for skin conditions, cancer side effects, and neurological disorders. Hoth Therapeutics generates revenue through the development and eventual commercialization of its therapeutic products. It leverages its pipeline of HT-001, HT-KIT, HT-TBI, and HT-ALZ for dermatological, oncological, and neurological markets. The company also capitalizes on third-party assets, such as a lupus treatment, to expand its portfolio. Its primary customers include healthcare providers and patients requiring innovative solutions for unmet medical needs. The company’s business model centers on advancing its therapeutic pipeline to market readiness, with products targeting high-need areas like cancer side effects, neurological diseases, and inflammatory skin conditions. It relies on partnerships for third-party asset development, such as the lupus treatment, to complement its internal research. Hoth Therapeutics aims to monetize its assets through licensing agreements, product sales, and potential future partnerships in the pharmaceutical sector. Hoth Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hoth Therapeutics stock

P/B (Price-to-Book Ratio) of Hoth Therapeutics is 2.33 in 2025.

P/B (Price-to-Book Ratio) of Hoth Therapeutics changed from 2.08 to 2.33, representing a 11.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Hoth Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Hoth Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Hoth Therapeutics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Hoth Therapeutics